🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

TrialNet Pathway to Prevention of T1D

Recruitingn/aAges 2 Years - 45 YearsAllUniversity of South Florida
NCT00097292 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T1DM (Pathway to Prevention Study) has been designed to clarify this picture, and in so doing, will contribute to the development and implementation of studies aimed at prevention of and early treatment in T1DM. Purpose: TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada,

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Individuals 2 to 45 years old who have an immediate family member with type 1 diabetes (such as a child, parent, or sibling) * Individuals 2-20 years old who have an extended family member with type 1 diabetes (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling) * Those aged 2 years to 45 years who are not family members and are known to have 1 or more islet antibodies Exclusion Criteria: To be eligible a person must not: * Have diabetes already * Have previous or current use of medications for the control of hyperglycemia/diabetes. * Currently be using immunosuppressive or immunomodulatory agents (topical and inhaled agents are acceptable) * Have known severe active diseases, and/or diseases which are likely to limit life expectancy or lead to the use of chronic immunosuppressive or immunomodulatory therapies during the course of the study
💊

What it tests

  • Not listed
📍

Where

22 sites
Childrens Hospital of Orange County
Orange, United States
University of California San Francisco
San Francisco, United States
Stanford University Medical Center
Stanford, United States
Barbara Davis Center for Childhood Diabetes
Denver, United States
Yale University School of Medicine
New Haven, United States
University of Florida
Gainesville, United States
Emory Children's Center
Atlanta, United States
Riley Hospital for Children, Indiana University
Indianapolis, United States

…and 14 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy